The MoU supports the Kingdom’s healthcare transformation under Saudi Vision 2030 by advancing specialized care models and ...

French biopharma Servier has bought up Danish cancer biotech Symphogen as it looks to bolster its immuno-oncology pipeline. The deal, financial terms of which have not been made public, unusually, ...

PARIS (Reuters) - Jacques Servier, founder and president of France's second-largest drugmaker, has died before his trial over Mediator, a weight-loss pill at the centre of the country's biggest public ...

The French drugmaker will invest 15 million euro in 2026 to build the platform, which will coordinate R&D, manufacturing ...

U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally BOSTON, May 28, 2025 /PRNewswire/ -- Servier today announced ...

French drugmaker to commit €15 million annually to SPC development and exports for cardiometabolic and venous diseases ...

The MarketWatch News Department was not involved in the creation of this content. -- Servier reported Group revenues of EUR6.9 billion for 2024/25, up 16.2% from 2023/24. -- Growth over the financial ...

SURESNES, France, Sept. 8, 2025 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement ...

Presentations include seven company-sponsored abstracts and 11 investigator-initiated studies. Results from a Phase 1 analysis of TIBSOVO ® (ivosidenib) in patients with newly diagnosed IDH1-mutated ...

FILE - In this May 21, 2013 file photo, Jacques Servier, founder of Servier Laboratories, is pictured during the opening of the trial of the so-called Mediator case, a drug allegedly linked to ...

International pharmaceutical group Servier has expanded its partnership with Google Cloud to accelerate the research and development (R&D) of pharmaceuticals. Servier and Google Cloud have entered ...

The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer. The IDH1/2 inhibitor, which can be dosed ...